RNA technology takes on diabetes: first human trial of exenatide nanoparticle injection

NCT ID NCT07347080

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a single dose of a new type of exenatide injection (CR059) in 9 Chinese adults with type 2 diabetes. The exenatide is delivered using circular RNA wrapped in lipid nanoparticles, a technology similar to some vaccines. The main goal is to check safety and tolerability, while also looking at how the drug moves through the body and affects blood sugar. Because it's a very small, first-in-human study, it's mainly about gathering initial safety data.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
exenatide circular RNA-lipid nanoparticle injection (CR059)
What this could lead to
If it works, this could lead to a new way to deliver exenatide for better blood sugar control in type 2 diabetes.
What could go wrong
This is a very early, small trial with only 9 people, so it may not show clear benefits or could have unexpected side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T2DM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The First Affiliated Hospital of Henan University of Science and Technology

    RECRUITING

    Luoyang, Henan, 310015, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.